The role of biomarkers in the early diagnostics of breast cancer
Open Access
- 13 December 2020
- journal article
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 16 (4) , 35-40
Abstract
One of the main priorities in modern oncology is the identification and clinical application of biomarkers that can be helpful in the diagnostics and prognostication of cancer. The aim of this article was to review biomarkers for early diagnosis and prediction of prognosis of breast cancer. There were reviewed three main groups of biomarkers in this article: familial breast cancer biomarkers with high and low penetration (BRCA1, BRCA2, TP53, etc.), biomarkers of breast cancer molecular subtypes (luminal A and luminal B, HER2/neu, basal and low in claudine) and biomarkers of early stage breast cancer progression (multigenic panels).Keywords
This publication has 26 references indexed in Scilit:
- Poor-prognosis estrogen receptor- positive disease: present and future clinical solutionsTherapeutic Advances in Medical Oncology, 2012
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerJAMA, 2007
- A recurrent mutation in PALB2 in Finnish cancer familiesNature, 2007
- Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility allelesNature Genetics, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- The molecular outlookNature, 2002
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesThe American Journal of Human Genetics, 1998
- Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21Science, 1990